Last Updated on October 11, 2024 by The Health Master
Glenmark Pharma has received final approval by the US Food and Drug Administration (USFDA) for its Lacosamide tablets USP, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB.
The company plans to launch the product immediately, Glenmark Pharma said in a statement.
According to IQVIA sales data for the 12-month period ending January 2022, the Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg market achieved annual sales of approximately $1.7 billion, the statement added.
USFDA approves drug for treatment of Seizures associated with rare disease
USFDA approves new Bristol Myers cancer Immunotherapy
USFDA approves first generic of Symbicort to treat Asthma and COPD
USFDA gives nod to Lupin for Vigabatrin for Oral Solution
USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg
USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets
Pharma firm Director and 4 others held for illegal export of Tramadol
CDSCO penal asked for more data on Tildrakizumab
USFDA approves drug for treatment of Seizures associated with rare disease
Drug alert: 40 out of 1221 samples declared as NSQ in February 2022
Govt releases draft Uniform Code for Medical Devices Marketing Practices
USFDA approves new Bristol Myers cancer Immunotherapy
US Pharmacopeia report finds high reliance on Indian manufacturers for APIs
19 Indian Pharma Companies get licence to make Pfizer’s oral generic
USFDA approves first generic of Symbicort to treat Asthma and COPD
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
